No Data
No Data
Junshi Bio (01877) has been removed from the Hang Seng Composite SmallCap Index.
On August 16th, Hang Seng Indexes Company published the latest quarterly review results, in which Junshi Bio (01877) was removed from the Hang Seng Composite SmallCap Index. The change will be implemented after the market closes on September 6th, 2024 (Friday) and will take effect from September 9th, 2024 (Monday).
Junshi Bio (01877.HK) held a board of directors meeting on August 30 to consider and approve its mid-year performance
Junshi Bio (01877.HK) announced on August 15th that the board of directors will hold a meeting on August 30th, 2024 (Friday) to consider and approve the group's mid-term performance for the six months ending on June 30th, 2024, as well as to handle other matters.
JUNSHI BIO: DATE OF BOARD MEETING
Open Source Securities: Bullish on the opportunity of PCSK9 inhibitors in the lipid-lowering market.
Bullish on the opportunity of PCSK9 inhibitors in the lipid-lowering market, with a focus on the market potential of siRNA drugs with higher adherence. Leading companies with strategic layout are expected to benefit.
China Accepts Shanghai Junshi Biosciences' Supplemental Application for Melanoma Treatment
Express News | Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
No Data